Generex Biotechnology Corp.
| OTC Markets: GNBT
Generex Biotechnology Corp. engages in the research, development and commercialization of drug delivery systems and technologies. The company focuses on proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. Its product, Oral-lyn is an insulin spray formulation used for the treatment of type-1 and type-2 diabetes. The company's research and development of drug delivery systems and technologies is for the metabolic and immunological diseases. Generex Biotechnology was founded by Anna E. Gluskin and Rose C. Perri in September 1997 and is headquartered in Toronto, Canada.